Inventor · disambiguated record
Patrick Hoffmann
Also filed as: HOFFMANN PATRICK
40 granted patents·34 pending applications·422 citations·filing 2004–2025
98Inventor score
Top patents by PatentIndex Score
74 records- 0198US9340621B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted May 17, 2016·91 cites·15 claims
- 0297US10294300B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted May 21, 2019·37 cites·16 claims
- 0397US9150664B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted Oct 6, 2015·64 cites·15 claims
- 0496US11591396B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2020·Granted Feb 28, 2023·5 cites·33 claims
- 0595US11472886B2Cross-species-specific PSMAxCD3 bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted Oct 18, 2022·3 cites·13 claims
- 0695US10301391B2BCMA and CD3 bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2017·Granted May 28, 2019·28 cites·19 claims
- 0794US9765157B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2015·Granted Sep 19, 2017·13 cites·14 claims
- 0894US9598500B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted Mar 21, 2017·22 cites·15 claims
- 0993US10683351B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Jun 16, 2020·4 cites·24 claims
- 1093US10519241B2Antibody constructs for EGFRVIII and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Dec 31, 2019·16 cites·22 claims
- 1192US10781264B2PSMA and CD3 bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2017·Granted Sep 22, 2020·8 cites·22 claims
- 1292US10766969B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted Sep 8, 2020·8 cites·29 claims
- 1391US11434302B2Bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2017·Granted Sep 6, 2022·7 cites·19 claims
- 1490US12281176B2Binding molecules for BCMA and CD3AMGEN INC·Filed 2021·Granted Apr 22, 2025·1 cites·7 claims
- 1590US10752694B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2014·Granted Aug 25, 2020·11 cites·15 claims
- 1690US9688760B2Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domainsAMGEN RES MUNICH GMBH·Filed 2014·Granted Jun 27, 2017·17 cites·10 claims
- 1790US9587036B2Cross-species-specific PSMAxCD3 bispecific single chain antibodyKUFER PETER·Filed 2011·Granted Mar 7, 2017·24 cites·34 claims
- 1889US11084876B2Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domainsAMGEN RES MUNICH GMBH·Filed 2017·Granted Aug 10, 2021·4 cites·14 claims
- 1988US11987633B2Cross-species-specific single domain bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted May 21, 2024·1 cites·27 claims
- 2087US11661462B2Optimized cross-species specific bispecific single chain antibody contructsAMGEN RES MUNICH GMBH·Filed 2015·Granted May 30, 2023·4 cites·12 claims
- 2187US10059766B2Antibody constructs for CDH19 and CD3AMGEN RES MUNICH GMBH·Filed 2014·Granted Aug 28, 2018·9 cites·17 claims
- 2286US11447567B2Antibody constructs for FLT3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Sep 20, 2022·4 cites·18 claims
- 2386US11155629B2Method for treating glioblastoma or glioma with antibody constructs for EGFRVIII and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Oct 26, 2021·2 cites·20 claims
- 2486US8518403B2Expression-enhanced polypeptidesHOFFMANN PATRICK·Filed 2005·Granted Aug 27, 2013·24 cites·22 claims
- 2584US12435139B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2022·Granted Oct 7, 2025·0 cites·12 claims
- 2684US11352433B2BCMA and CD3 bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2019·Granted Jun 7, 2022·2 cites·23 claims
- 2783US2025340639A1Antibody constructs for dll3 and cd3AMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 2882US12297292B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2017·Granted May 13, 2025·2 cites·12 claims
- 2982US10851170B2Antibody constructs for CD70 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Dec 1, 2020·3 cites·18 claims
- 3081US2022251243A1Binding molecules for bcma and cd3AMGEN INC·Filed 2022·Application pending·0 cites
- 3179US11498964B2Antibody constructs for CDH19 and CD3AMGEN RES MUNICH GMBH·Filed 2018·Granted Nov 15, 2022·1 cites·17 claims
- 3278US12441796B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2022·Granted Oct 14, 2025·0 cites·17 claims
- 3378US9486475B2PPS for the prevention of potential adverse effects caused by CD3 specific binding domainsAMGEN RES MUNICH GMBH·Filed 2014·Granted Nov 8, 2016·4 cites·14 claims
- 3478US2025346684A1Binding molecules for bcma and cd3AMGEN INC·Filed 2025·Application pending·0 cites
- 3578US2024400673A1Antibody constructs for msln and cd3AMGEN RES MUNICH GMBH·Filed 2023·Application pending·0 cites
- 3676US12304952B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2021·Granted May 20, 2025·0 cites·16 claims
- 3776US12281175B2Binding molecules for BCMA and CD3AMGEN INC·Filed 2020·Granted Apr 22, 2025·0 cites·16 claims
- 3876US2025092133A1Bispecific antibody constructs for cdh3 and cd3AMGEN RES MUNICH GMBH·Filed 2024·Application pending·0 cites
- 3975US12281172B2Cross-species-specific PSMAxCD3 bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted Apr 22, 2025·0 cites·18 claims
- 4075US12152078B2Nucleic acids encoding anitbody constructs binding EGFR VIII and CD3AMGEN RES MUNICH GMBH·Filed 2021·Granted Nov 26, 2024·0 cites·24 claims
- 4175US2025333535A1Bispecific single chain antibody construct with enhanced tissue distributionAMGEN RES MUNICH GMBH·Filed 2024·Application pending·0 cites
- 4274US11884720B2Antibody constructs for MSLN and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Jan 30, 2024·1 cites·23 claims
- 4374US2025163179A1CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODYAMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 4472US2023057728A1Long life polypeptide binding moleculesAMGEN RES MUNICH GMBH·Filed 2022·Application pending·0 cites
- 4572US2023192884A1Bispecific t cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2022·Application pending·0 cites
- 4670US11028171B2Bispecific antibody constructs for CDH3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Jun 8, 2021·1 cites·14 claims
- 4769US12428491B2PSMA and CD3 bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2020·Granted Sep 30, 2025·0 cites·28 claims
- 4868US2025333537A1Psma and cd3 bispecific t cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 4968US2025163177A1Bispecific t cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 5067US2011293619A1CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODYKUFER PETER·Filed 2009·Application pending·0 cites
Showing the top 50 of 74 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Patrick Hoffmann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →